$1.57 -0.04 (-2.47%)

Aptevo Therapeutics Inc (APVO)

Aptevo Therapeutics Inc. is a biotechnology company focused on developing innovative immuno-oncology and hematology therapies. The company specializes in leveraging its proprietary ADAPTIR® bispecific antibody platform to create treatments aimed at improving outcomes for patients with cancer and blood disorders. Founded with a focus on immunotherapy, Aptevo integrates advanced scientific research with clinical development to address unmet medical needs.

🚫 Aptevo Therapeutics Inc does not pay dividends

Company News

Aptevo Reports 85% Remission in Q2
The Motley Fool • Na • August 11, 2025

Aptevo Therapeutics reported a net loss of $8.40 per share in Q2 2025, significantly better than analyst estimates. The company's lead bispecific antibody, mipletamig, showed promising 85% remission rates in acute myeloid leukemia trials, and raised $15.9 million in equity to extend its cash runway.

Why Bloom Energy Group Shares Are Trading Higher By 12%; Here Are 20 Stocks Moving Premarket - Benzinga
Benzinga • Avi Kapoor • July 17, 2024

Bloom Energy shares jumped 12.1% after announcing a strategic partnership with CoreWeave to deploy its fuel cells for on-site power generation at a data center. Several other stocks also saw significant pre-market movements, both positive and negative.

Why You Should Bet on 5 Top-Ranked Stocks With Rising P/E
Zacks Investment Research • Sanghamitra Saha • May 28, 2024

Tap five stocks with increasing P/E ratios to try out an out-of-the-box approach. These are Vita Coco Company (COCO), AMC Entertainment (AMC), Hyperfine (HYPR), Aptevo Therapeutics (APVO) and CLEAR Secure (YOU).

Retail capitulation may be a new year's gift for the stock market, says this analyst
MarketWatch • MarketWatch • December 12, 2022

Retail investors are skittish about this market, and understandably. Our call of the day says that may only help lure back influential investors in the new year.